The standard 1st line therapy for HF includes quadruple combination of SGLT2 inhibitor, ACEi (angiotensin converting enzyme inhibitor)/ARNI (angiotensin receptor–neprilysin inhibitor), betablocker and MRA (mineralocorticoid receptor antagonist). This evidence concerns the gene SLC5A2 and hydrops fetalis.